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ABSTRACT
Background. Cholangiolocellular carcinoma (CoCC) has
distinct pathological characteristics, and CoCC is consid-
ered to originate from hepatic progenitor or stem cells.
However, the surgical outcome of CoCC has not been
clarified in detail.
Methods. We retrospectively studied 275 patients with
intrahepatic cholangiocarcinoma (ICC) who underwent
hepatectomy between 1990 and 2011. Surgical outcomes
were compared between 29 patients with CoCC and 130
patients with mass-forming (MF) type ICC since all
patients with CoCC showed MF type on macroscopic
findings.
Results. The number of patients with chronic liver disease
was significantly higher in the CoCC group than in the ICC
group. The number of patients with abnormal levels of
CA19-9 was significantly lower in the CoCC group than in
the ICC group. Portal vein invasion and intrahepatic
metastasis were significantly lower in patients with CoCC
group than in the ICC group. In the CoCC group, 15 of 28
patients survived for more than 5 years after curative sur-
gery whereas 15 of 102 patients with ICC survived for
more than 5 years after curative surgery. The 5-year sur-
vival rate was significantly higher in patients with CoCC
(75 %) than in patients with ICC (33 %, p = 0.0005).
Multivariate analysis showed CoCC, absence of portal vein
invasion or hepatic vein invasion, and absence of
intrahepatic metastasis to be significant independent prog-
nostic factors for overall survival in patients with MF-type
ICC and CoCC.
Conclusions. CoCC is rare, but patients with CoCC had
special characteristics with favorable long-term survival
due to its less invasive histopathologic characteristics.
INTRODUCTION
Cholangiolocellular carcinoma (CoCC) is a rare type of
primary liver cancer. Steiner and Higginson described the
distinct pathological characteristics of CoCC, which
derives from the cholangioles or canals of Hering.1 This
tumor was classified as a special type of intrahepatic
cholangiocarcinoma (ICC).2,3 However, as a result of
recent advancements in the study and knowledge of hepatic
progenitor or stem cells, CoCC is considered to originate
from hepatic progenitor or stem cells.4–7
ICC is a primary liver cancer derived from cholangiocytes
in the biliary tree. The biliary tree is divided into the extra-
hepatic and intrahepatic bile ducts. The hilar bile ducts are
lined with cylindrical mucin-producing cholangiocytes. In the
liver, large intrahepatic bile ducts (segmental and septal bile
ducts) are lined with similar mucin-producing cells, whereas
small intrahepatic bile ducts (interlobular bile ducts and
ductules) are lined with mucin-negative cuboidal cholangio-
cytes. The ductules contain hepatic progenitor cells that can
differentiate into both hepatocytes and cholangiocytes.
Therefore, hepatic progenitor cell derived tumors can display
varying hepatocytic and/or cholangiocytic differentiation
characteristics within the same tumor. CoCC is considered a
hepatic progenitor cell derived tumor.4–7 Therefore, CoCC
exhibits a mass-forming (MF) type tumor at the periphery of
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the liver and often shows clinical and imaging findings similar
to those of hepatocellular carcinoma (HCC). The pathological
features and imaging findings of CoCC have been published,
but there has been 1 previous report on the surgical outcomes
of CoCC.4–13 Therefore, we evaluated the surgical outcomes
of patients with CoCC.
PATIENTS AND METHODS
Patients
Between 1990 and 2011, 274 patients underwent initial
hepatic resection for ICC at our institute. A diagnosis of
CoCC was made in 29 patients and ICC in 245 patients
according to the General Rules for the Clinical and Path-
ological Study of Primary Liver Cancer.8 In 245 patients
with ICC, a further diagnosis was made of MF type in 130
patients, periductal infiltrative (PI) type in 24 patients,
intraductal growth (IG) type in 15 patients, and MF?PI
type in 76 patients based on the macroscopic findings of
ICC. We retrospectively studied 29 patients with CoCC
and 130 patients with MF-type ICC because all patients
showed MF type on macroscopic findings. The patient
characteristics are shown in Table 1. Written informed
consent was obtained from all patients before hepatectomy.
This study was approved by the ethics committee of Tokyo
Women’s Medical University.
Preoperative Examination
Serum hepatitis B surface antigen, hepatitis C antibody,
and indocyanine green retention rate at 15 min were






Sex, male 14 (48 %) 96 (74 %) 0.007
Age, years; median
(range)
65 (30–84) 65.5 (26–83) 0.94
Chronic hepatitis or cirrhosis









10.5 (5–52) 9 (1–56) 0.0179
AFPa
Median (range) 8 (1–6826) 5 (1–5854) 0.13
[10 ng/ml 13/27 (48 %) 40/120 (33 %) 0.18
CA19-9b
Median (range) 17 (1–113) 67 (1–12,000,000) 0.47
[37 U/ml 8/27 (30 %) 71/115 (62 %) 0.0025
Arterial CT findings,
high density
13/27 (48 %) 13/130 (10 %) \0.0001
Preoperative diagnosis
ICC 10 (34 %) 83 (64 %) 0.0064
HCC 16 (55 %) 40 (31 %)
Metastasis 1 (4 %) 6 (4 %)




13 (45 %) 81 (62 %) 0.17
Sectionectomy 6 (21 %) 34 (18 %)
Segmentectomy 10 (34 %) 26 (20 %)
Lymph node
dissection present
11 (38 %) 69 (53 %) 0.14
Bile duct resection
present
4 (14 %) 23 (18 %) 0.79
Curative resection, R0 29 (97 %) 102 (78 %) 0.0225
Tumor size, cm;
median (range)
3.5 (0.6–13) 6 (1–19) 0.0069
Portal vein invasion,
present
15 (52 %) 92 (71 %) 0.0481
Hepatic vein invasion,
present
4 (14 %) 26 (20 %) 0.44
Intrahepatic
metastasis, present
3 (10 %) 54 (42 %) 0.0015
T classification
T1 8 (28 %) 19 (15 %) 0.15
T2 20 (69 %) 97 (67 %)
T3 1 (3 %) 14 (9 %)
N classification, N1 4 (14 %) 38 (29 %) 0.09







Mucus secretion, present 8 (28 %) 81 (62 %) 0.0007
CK19, present 27 (93 %) 118 (91 %) 0.99
Growth pattern,
replacement
24 (83 %) 26 (20 %) \0.0001
Portal tract within the
tumor, present
28 (97 %) 91 (70 %) 0.0017
Ductal plate malformation,
present
10 (34 %) 4 (3 %) \0.0001
TNM classifications were determined according to the American Joint Com-
mittee on Cancer (AJCC)/International Union Against Cancer (UICC) TNM
Classification and Stage Groups for ICC, 7th ed
CoCC cholangiolocellular carcinoma, ICC intrahepatic cholangiocarcinoma,
HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatohep-
atitis, ICGR15 indocyanine green retention rate at 15 min, AFP alpha-
fetoprotein, CA19-9 cancer-associated carbohydrate antigen 19-9, HCC hepa-
tocellular carcinoma
a 147 patients were assessed
b 142 patients were assessed
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examined preoperatively in all patients. In 29 patients with
CoCC, serum alpha-fetoprotein (AFP) and cancer-associ-
ated carbohydrate antigen 19-9 (CA19-9) levels were
examined preoperatively in 27 patients. Of 29 patients with
CoCC, 27 underwent serial abdominal axial single-helical
multiphase computed tomography (CT) scans (X vigor;
Toshiba, Nasu, Japan) or multidetector helical CT (Aqui-
lion 4 or 16; Toshiba) scans, whereas 2 patients could not
undergo the procedure because of iodine allergy.
Hepatic Resection
All patients underwent hepatectomy, and the choice of
resection was made on the basis of the tumor size, tumor
location, preoperative diagnosis, and liver function. In
patients who were given a diagnosis of HCC preopera-
tively, hepatectomy without lymph node dissection was
performed. On the other hand, in patients who were given a
diagnosis of ICC preoperatively, hepatectomy with lymph
FIG. 1 CoCC and ICC showed
MF type on macroscopically (a)
and (e). The CoCC cells were
proliferated showing small
glands, and the size of the small
glandular formation was similar
or less than the size of normal
interlobular ductules (arrows)
(b, 920). CoCC cells
proliferated replacing the
hepatocytes of the surrounding
hepatic parenchyma (arrows),
and a remaining portal tract
within the tumor (asterisk) was
seen on VHE staining (c, 94).
Immunohistochemically, CoCC
cells were membranous positive
for EMA (d, 920). The ICC
cells were proliferated showing
irregular glands, and the size of
the glands was larger than the
size of normal interlobular
ductules (f, arrow in small
square, 920). The ICC grew
compressing the normal
hepatocytes (arrows, 910), and
no portal tract within the tumor
was seen (g).
Immunohistochemically, ICC
cells were cytoplasmic positive
staining for epithelial membrane
antigen (h, 920)
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node dissection (around the hepatoduodenal ligament, the
common hepatic artery, or behind the pancreas head) was
performed. Extrahepatic bile duct resection and recon-
struction was performed when either HCC or ICC involved
the bile duct in the perihilar region. Surgical procedures are
shown in Table 1. The terminology of liver resection was
determined according to the Terminology Committee of
the International Hepato-Pancreato-Biliary Association of
2000.14
Pathological Examination
Pathologically, CoCC cells were defined as small gland-
forming cells (Fig. 1). The tumor was composed of small
cuboidal cells with round nuclei, basophilic cytoplasm, no
nucleoli, and various degrees of fibrous stroma with or
without mucin production.8,9 The size of the small glan-
dular formation was similar or less than the size of normal
interlobular ductules.10 The CoCC cells sometimes formed
antlerlike anastomosing and ductal plate malformation-like
patterns.8,15,16 CoCC cells were further confirmed by either
positive staining for cytokeratin 19 (CK19), membranous
positive staining for mucin core protein 1 (MUC-1), and/or
membranous positive staining for epithelial membrane
antigen (EMA), but no staining for hepatocyte paraffin 1
(Hep1).10,11
ICC cells were defined as large glandular forming,
composed of cuboidal and/or columnar cells with round
nuclei, no nucleoli, basophilic cytoplasm, and various
degrees of fibrous stroma with or without mucin production
(Fig. 2).8,9,15 The size of the glandular formation was lar-
ger than the size of normal interlobular ductules.11 The ICC
cells sometimes formed papillary and solid patterns. ICC
cells were confirmed by either positive staining for CK19,
cytoplasmic positive staining for MUC-1, and/or cyto-
plasmic positive staining for EMA, but negative staining
for Hep1.10,11
A pathologist (M.N.) with liver expertise confirmed the
diagnoses on the basis of macroscopic, microscopic, and
immunohistological findings. When CoCC cells and ICC
cells coexisted in the same tumor and the CoCC cells were
predominant within the tumor (50 % or more), the tumor
was given a diagnosis of CoCC.8 When HCC cells coex-
isted in the same tumor and the HCC cells accounted for
10 % or more of all cells within the tumor, the tumor was
diagnosed as combined hepatocellular and cholangiocar-
cinoma (CHC).7,17,18 Mucus secretion was confirmed by
Alcian blue and periodic acid Schiff double staining.
Growth pattern at the periphery of the tumor was classified
into replacement growth pattern (cancer cell growth
replacing the normal hepatocytes) or compressive growth
pattern (cancer cell growth compressing the normal hepa-
tocytes).6,8,9,15 The number of remaining portal tracts at the
periphery within the tumor of each patient was assessed on
Victoria blue with hematoxylin and eosin (VHE) staining
with 4 9 magnification. TNM classifications were deter-
mined according to the American Joint Committee on
Cancer (AJCC)/International Union Against Cancer
(UICC) TNM Classification and Stage Groups for ICC,
seventh edition.19 Furthermore, another pathologist (NY)
with liver expertise confirmed the diagnoses, and all
patients were classified according to their new classifica-
tion for ICC.15,16
Follow-Up and Treatment of Patients with Recurrence
After surgery, patients were followed up every 4–
12 weeks at the outpatient department of our institution.
Ultrasonography or CT was performed once every 3–
4 months. Survival duration was defined as the time from
hepatectomy to the date of death or last contact. When a
solitary CoCC or ICC had recurred in the liver, repeat
hepatectomy or radiofrequency ablation was performed.
When multiple tumors had recurred in the liver, transar-
terial chemoembolization (TACE) was performed. If CoCC
or ICC recurred in the liver and/or other organs including
lymph nodes, systemic chemotherapy or best supportive
care was performed.
Statistical Analysis
Categorical variables were assessed using the Chi square
test. Continuous variables were expressed as the median
and assessed using the nonparametric Mann–Whitney U
test. The overall survival rates among the patients were
calculated by the Kaplan–Meier method and compared
with the log rank test. Statistical significance was indicated
by p values less than 0.05 (p \ 0.05). We used JMP soft-






































FIG. 2 Survival curves of patients with CoCC and ICC who
underwent curative surgery
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RESULTS
Patient Characteristics
Patient characteristics are shown in Table 1. The num-
ber of patients with chronic liver disease was significantly
higher in the CoCC group than in the ICC group. In the
CoCC group, 8 of 27 patients (30 %) showed abnormal
levels of CA19-9, and the number of patients with abnor-
mal levels of CA19-9 was significantly lower in the CoCC
group than in the ICC group. The number of patients with
high density on arterial CT findings was significantly
higher in the CoCC group than in the ICC group. The
number of patients who were given a diagnosis of HCC
preoperatively was significantly higher in the CoCC group
than in the ICC group. The number of patients with sur-
gical procedure, lymph node dissection, and bile duct
resection did not differ between groups.
Tumor Characteristics
Macroscopically, all patients showed the MF type in
both groups. The median tumor size was significantly
smaller in the CoCC group than that in the ICC group. In
the CoCC group, 3 of 29 patients showed intrahepatic
metastasis, whereas in the ICC group, 54 of 130 patients
showed intrahepatic metastasis. The number of patients
with intrahepatic metastasis was significantly lower in the
CoCC group than in the ICC group. In the CoCC group, 15
of 29 patients showed portal vein invasion, whereas in the
ICC group, 92 of 130 patients showed portal vein invasion.
The number of portal vein invasions was significantly
lower in the CoCC group than in the ICC group. The
number of patients with lymph node metastasis did not
differ between the groups. In the CoCC group, 24 of 29
patients showed the replacement growth pattern. On the
other hand, in the ICC group, 104 of 130 patients showed
compression growth pattern. The number of patients with
the replacement growth pattern was significantly higher in
the CoCC group than in the ICC group. In the CoCC group,
28 of 29 patients showed portal tracts within the tumor, and
the number of patients with the portal tracts within the
tumor was significantly higher in the CoCC group than in
the ICC group. According to Nakanuma’s classification, 10
of 29 patients with CoCC showed an area with ductal plate
malformation like pattern within the tumor.
Surgical Outcomes
Of 29 patients with CoCC, 28 patients underwent
curative surgery, and 1 patient underwent noncurative
surgery because of multiple tumors in the remnant liver.
No patient died within 30 days after hepatectomy. There
were 15 patients who survived for more than 5 years after
curative surgery. The survival rate for patients with CoCC
who underwent curative surgery was 75 % at 5 years, and
the median survival was 63 months (ranging from 0.6 to
183 months). In the ICC group, 102 of 130 patients
underwent curative surgery, and 15 patients survived for
more than 5 years. There was 1 patient who died due to
lactic acidemia on postoperative day 2 because this patient
underwent dialysis for the complication of chronic renal
failure. The survival rate for 102 patients with ICC who
underwent curative surgery was 33 % at 5 years, and
median survival was 19 months (ranging from 0.1 to
184 months). The 5-year survival rate was significantly
higher in the CoCC group than in the ICC group
(p = 0.0005, Fig. 2).
Recurrence
In the CoCC group, tumor recurrence occurred in 16 of
28 patients who underwent curative surgery. The most
frequent recurrence site was the liver (Table 2). The
recurrence pattern did not differ significantly between
groups. Although no lymph node recurrence was seen in
the CoCC group, 20 of 69 patients in the ICC group
showed lymph node recurrence (p = 0.0095). The 5-year
recurrence-free survival rate was significantly higher in the
CoCC group (41 %) than in the ICC group (26 %,
p = 0.0408).
Prognostic Factors
The univariate analysis of prognostic factors for survival
with 14 variables (sex, age, chronic hepatitis, ICGR15,
AFP, CA19-9, surgical procedure, lymph node dissection,
tumor size, portal vein invasion, hepatic vein invasion,
intrahepatic metastasis, lymph node metastasis, tumor







Liver 12 (75 %) 33 (48 %) 0.09
Liver and other organs 1 (6 %) 11 (16 %) 0.45
Liver and lymph node 0 5 (7 %) 0.58
Liver, other organs, and lymph
node
0 3 (4 %) 0.39
Other organ 3 (19 %) 4 (6 %) 0.12
Lymph node 0 8 (12 %) 0.34
Lymph node and other organs 0 4 (6 %) 0.99
Unknown 0 1 (1 %)
Other organs refers to lung, bone, or peritoneum
CoCC cholangiolocellular carcinoma, ICC intrahepatic
cholangiocarcinoma
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diagnosis) in patients with MF-type ICC and CoCC who
underwent curative surgery is summarized in Table 3. The
univariate prognostic factors were entered into a multi-
variate model to identify independent predictors of
survival. Multivariate analysis showed CoCC, portal vein
invasion, hepatic vein invasion, and intrahepatic metastasis
to be significant independent prognostic factors for overall
survival in patients with MF-type ICC and CoCC.
DISCUSSION
CoCC is a rare type of primary liver cancer, and it was
classified as a special type of ICC.1–3 The pathologic
characteristics of CoCC have been described, but surgical
outcomes after hepatectomy in patients with CoCC have
not been clarified in detail. Komuta et al.7 reported that 6 of
30 patients (20 %) with CoCC survived for more than
5 years after hepatectomy. In our present study, 15 of 28
patients (47 %) survived for more than 5 years after
curative surgery. The survival rate for patients with CoCC
who underwent curative surgery was 75 % at 5 years, and
the median survival was 63 months. The 5-year survival
rate was significantly higher in the CoCC group than in the
ICC group (33 %, p = 0.0005). CoCC is rare, but patients
with CoCC showed favorable long-term survival after
curative surgery.
ICC often invades the portal vein and spreads to the
liver as intrahepatic metastasis via the portal invasion. The
rate of intrahepatic recurrence after curative surgery is
particularly high, and the 5-year survival rate is 30–40 % in
patients with the MF type of ICC.20–28 Several prognostic
factors for survival in patients with ICC such as portal vein
invasion, tumor number, and serum CA19-9 level are
known. Portal invasion and intrahepatic metastasis of ICC
are often seen in patients with abnormal levels of CA19-
9.29 In our present study, the numbers of patients with
portal vein invasion, intrahepatic metastasis, and abnormal
levels of CA19-9 were significantly lower in the CoCC
group than in the ICC group. CoCC was less invasive to the
portal vein, as the number of patients with remaining portal
tracts within the tumor was significantly higher in the
CoCC group than in the ICC group. Therefore, the number
of patients with intrahepatic metastasis and abnormal levels
of CA19-9 was significantly lower in the CoCC group than
in the ICC group. Furthermore, the 5-year overall survival
rate and recurrence-free survival rate were significantly
higher in the CoCC group than in the ICC group. More-
over, multivariate analysis showed CoCC to be a
significant independent prognostic factor for survival in
patients with MF-type ICC and CoCC. CoCC is rare, but
patients with CoCC showed special characteristics such as
favorable long-term surgical outcome because of its less
invasive histopathologic characteristics.
Lymph node metastasis is known as one of the important
prognostic factors for survival in patients with ICC, and
lymph node recurrence after surgery is one of the most
intractable situations in patients with ICC.20,21,24–27 In the
present study, lymph node metastasis tended to be lower in
the CoCC group than in the ICC group. Moreover, no
lymph node recurrence of CoCC was seen in the present
study. Komuta et al.7 also reported that no lymph node
recurrence was seen in 29 patients with CoCC after sur-
gery. ICC cells spread with various progression patterns
along the Glissonean sheath (portal vein invasion, lym-
phatic invasion, perineural or intraneural invasion, and bile
duct invasion) even in its early stage.30,31 However, CoCC
may be less invasive to the lymphatic duct in the Glisso-
nean sheath because the number of patients with remaining
portal tracts within the tumor was significantly higher in
the CoCC group than in the ICC group.
The replacement growth pattern of CoCC has been
reported to be one of its important pathological charac-
teristics.7,8 Komuta et al.7 reported that all patients with
CoCC showed tumor cells proliferated as replacing the
surrounding normal liver cell cords and had remaining
portal tracts within the tumor. Kozaka et al. and Nakanuma
et al.6,15 reported a bile ductular carcinoma that was
thought to be derived from hepatic progenitor cells such as
CoCC, and bile ductular carcinoma showed replacing
TABLE 3 Univariate and multivariate analysis of prognostic factors
of patients with MF type ICC and CoCC






95 % CI p value
CA19-9, U/ml
B37 59 56 0.0012 0.605 0.344–1.051 0.07
[37 56 28 1
Portal vein invasion
Absent 48 52 0.0132 0.549 0.303–0.957 0.0341
Present 82 35 1
Hepatic vein invasion
Absent 108 47 0.0003 0.378 0.197–0.752 0.0064
Present 22 0 1
Intrahepatic metastasis
Absent 99 51 \0.0001 0.360 0.209–0.629 0.0004
Present 31 19 1
Tumor diagnosis
CoCC 28 75 0.0005 0.421 0.185–0.865 0.0175
ICC 102 33 1
CI confidence interval, CA19-9 cancer-associated carbohydrate anti-
gen 19-9, CoCC cholangiolocellular carcinoma, ICC intrahepatic
cholangiocarcinoma
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growth and portal tracts within the tumor. In our present
study, the majority of CoCC cases showed replacement
growth patterns and remaining portal tracts within the
tumor. These growth patterns of CoCC may correlate with
lower invasiveness to the portal vein and lymphatic duct in
the portal tract. Therefore, patients with CoCC showed
favorable long-term surgical outcome.
CoCC cells often proliferate heterogeneously, CoCC
presents ICC-like and HCC-like areas within the tumor,
and CoCC is considered to originate from hepatic pro-
genitor or stem cells.6,7,11 Therefore, CoCC is classified as
a stem-cell subtype of CHC according to the modified
fourth edition of the WHO classification.9 On the other
hand, CoCC is independent from ICC and is reclassified as
a type of primary liver cancer according to the Liver
Cancer Study Group of Japan.8 However, neither offers
immunohistochemical markers for the diagnosis of hepatic
progenitor or stem cells. In our present study, CoCC was
diagnosed when small gland-forming cells proliferated on
pathological findings, and these CoCC cells were further
confirmed by membranous positive staining for MUC-1
and/or EMA, because the usefulness of these staining
patterns for confirming CoCC cells, normal ductules, or
hepatic progenitor cells has been reported.10,11,32 Further-
more, when HCC cells coexisted in the CoCC and the HCC
cells accounted for 10 % or less, the tumor was diagnosed
as CoCC.7 However, when the HCC cells accounted for
10 % or more, the tumor was diagnosed as CHC. These
findings are important to differentiate the diagnosis of
CoCC and CHC since the surgical outcomes of these 2
entities are quite different.18
In conclusion, CoCC is rare, but patients with CoCC had
special characteristics with favorable long-term survival
due to its less invasive histopathologic characteristics.
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